Covid 19 Research using Clinical Trials (Home Page)
Report for D010698: Phobic Disorders NIH
(Synonyms: Phobic Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2901 | Therapist-guided one-session online exposure therapy according to (Öst, 1989) Wiki | 0.71 |
| drug342 | BI 706321 Wiki | 0.71 |
| drug54 | 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted) Wiki | 0.71 |
| drug2411 | Relaxation Therapy Wiki | 0.71 |
| drug696 | Cognitive Behavioral Therapy Wiki | 0.50 |
| drug2122 | Placebo Wiki | 0.04 |
There are 2 clinical trials
Clinical Trials
1 Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety
Anxiety is among the most prevalent, costly and disabling illnesses and tends emerge early in childhood. Cognitive behavioral therapy (CBT) is the first-line treatment for early life anxiety, but as many as 40% of young patients who receive CBT fail to get better. The proposed study will examine brain changes marking positive response to CBT for anxiety and how these changes may differ in children compared adolescents. By helping us to understand how CBT works, this study will pave the way for new treatments to stop anxiety early.
NCT02810171 Anxiety Disorders Social Anxiety Disorder Social Phobia Generalized Anxiety Disorder Separation Anxiety Disorder Specific Phobia Phobia Agoraphobia Panic Disorder Panic Attack Anxiety Behavioral: Cognitive Behavioral Therapy Behavioral: Relaxation Therapy MeSH:Disease Anxiety Disorders Phobic Disorders Panic Disorder Phobia, Social Agoraphobia Anxiety, Separation
HPO:Agoraphobia
Primary Outcomes
Description: Pre- to post-CBT changes in functional, connectivity and structural MRI measures of brain networks relevant for anxiety. Brain regions include the amygdala, anterior insula, dorsal anterior cingulate cortex (dACC) and ventrolateral prefrontal cortex (vlPFC). Functional activation and connectivity of these brain regions are assessed using simple computer tasks performed during MRI scanning. Tasks engage threat reactivity, self-regulatory control and the interaction of these processes. Structural connections between regions will be measured using a MRI technique that measures water diffusion in the brain.
Measure: Brain function/structure as assessed by Magnetic Resonance Imaging scans Time: Baseline and 12-weeks
Secondary Outcomes
Description: The Pediatric Anxiety Rating Scale (PARS) is a clinician-administered assessment to rate the severity of anxiety symptoms associated with common DSM-V anxiety disorders (social phobia, separation anxiety disorder, and generalized anxiety disorder) in children. The investigators are looking for decreases in anxiety severity ratings from pre- to post-treatment.
Measure: Pediatric Anxiety Rating Scale Time: weeks 0, 3, 6, 9, 12
2 Testing a Gamified App to Reduce Avoidance and Fear of Spiders in Spider Phobia
Primary Outcomes
Description: Pre- to post-CBT changes in functional, connectivity and structural MRI measures of brain networks relevant for anxiety. Brain regions include the amygdala, anterior insula, dorsal anterior cingulate cortex (dACC) and ventrolateral prefrontal cortex (vlPFC). Functional activation and connectivity of these brain regions are assessed using simple computer tasks performed during MRI scanning. Tasks engage threat reactivity, self-regulatory control and the interaction of these processes. Structural connections between regions will be measured using a MRI technique that measures water diffusion in the brain.
Measure: Brain function/structure as assessed by Magnetic Resonance Imaging scans Time: Baseline and 12-weeksSecondary Outcomes
Description: The Pediatric Anxiety Rating Scale (PARS) is a clinician-administered assessment to rate the severity of anxiety symptoms associated with common DSM-V anxiety disorders (social phobia, separation anxiety disorder, and generalized anxiety disorder) in children. The investigators are looking for decreases in anxiety severity ratings from pre- to post-treatment.
Measure: Pediatric Anxiety Rating Scale Time: weeks 0, 3, 6, 9, 12Mobile applications are more and more considered when implementing programs for treating mental disorders. The study aims to reduce avoidance and fear of spiders in spider-fearful individuals by combining exposure principles with gamification elements (e.g. narrative background, level progression, points, feedback). We investigate the efficacy of the gamified app in a remote online-therapy context.
NCT04423783 Spider Phobia Behavioral: 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted) Behavioral: Therapist-guided one-session online exposure therapy according to (Öst, 1989) MeSH:Phobic Disorders
Primary Outcomes
Description: Scores range from 0 ("participant refuses to enter the room with spider") to 12 ("participant holds the spider at least for 20 sec").
Measure: Change in avoidance behavior (Behavioral Approach Task; BAT) Time: Baseline; (after one-session exposure if applied); Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: The scale ranges from 0-31. High scores reflect high subjective levels and low scores low subjective levels of spider fear.
Measure: Change in spider fear (Spider Phobia Questionnaire; SPQ) Time: Baseline; Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: The scale ranges from 0-108. High scores reflect high subjective levels and low scores low subjective levels of spider fear.
Measure: Change in spider fear: Spider-Anxiety Questionnaire (FAS) Time: Baseline; Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Secondary Outcomes
Description: Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced disgust; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app
Measure: Change in disgust before and after playing the app Time: Before starting and immediately after completing the gameDescription: Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced arousal; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app
Measure: Change in arousal before and after playing the app Time: Before starting and immediately after completing the gameDescription: Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced anxiety; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app
Measure: Change in anxiety before and after playing the app Time: Before starting and immediately after completing the gameOther Outcomes
Description: Measures severity of depression; The scale ranges from 0-63: 0-13 minimal depressive symptoms; 14-19 mild symptoms; 20-28 moderate symptoms; 29-63 severe symptoms.
Measure: Beck Depression Inventory II (BDI-II) Time: Baseline, Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: Measures clinically relevant psychological symptoms.
Measure: Brief Symptom Inventory (BSI) Time: Baseline, Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: Standardised satisfaction measurement
Measure: German version of the Client Satisfaction Questionnaire (CSQ-8) Time: (after one-session exposure if applied), Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)Description: Questionnaire assessing the quality of new user-oriented health applications
Measure: Mobile Application Rating Scale (MARS) Time: Post-treatment (1-week after baseline)